Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's drug

This page shows the latest Alzheimer's drug news and features for those working in and with pharma, biotech and healthcare.

Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC

Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC

Biogen and Eisai have presented new data for their Alzhimer’s disease treatment Aduhelm at the Alzheimer’s Association International Conference (AAIC) following the controversial approval of the drug last month. ... An additional poster presentation

Latest news

More from news
Approximately 1 fully matching, plus 139 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimers disease: the search for a cure

    We are expecting to see the outcomes of an FDA priority review of the potential Alzheimer’s drug, aducanumab, this year. ... Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein.

  • Alzheimer’s: the search for a cure Alzheimers: the search for a cure

    Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia. ... Organisations including the Alzheimer’s Drug Discovery Foundation (ADDF) think combinations of molecules with these

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimers ahead of a cure

    Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate. ... It was just another in a string of late-stage

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimers disease R&D?

    This evidence has spurred research and led. organisations including the Alzheimer’s Drug Discovery Foundation and AC Immune to conclude that combination therapies may be needed to tackle such a complex ... Read more: Brain power: fresh approaches to

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimers drug discovery

    Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Bone Therapeutics looks to Pfizer for clinical head Bone Therapeutics looks to Pfizer for clinical head

    He has spent a majority of his career at Pfizer, where he held a number of senior roles including medical director for Pfizer Switzerland, European team leader for the Alzheimer's ... disease drug Aricept and medical team leader for its anti-inflammatory

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...